Delivering Therapy Where it Matters

Developing Innovative Therapy For Targeted Treatment of Difficult-to-Treat Cancers

Standard of Care Pancreatic Cancer Treatment May be Ineffective for Treating Tumors and is Often Accompanied by Debilitating Side Effects

The Phase 3 TIGeR-PaC clinical trial is a randomized multi-center study using RenovoRx’s innovative therapy platform, RenovoTAMP™ (RenovoRx Trans-arterial Micro-perfusion), to evaluate RenovoRx’s first product candidate, RenovoGem™, to treat locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (an FDA-approved chemotherapy). The goal of the study has a primary endpoint of overall survival and several secondary endpoints, including quality of life.

TIGeR-PaC is currently enrolling locally advanced, unresectable LAPC patients.

RenovoRx RenovoTAMP: Trans-Arterial Micro-Perfusion Therapy Platform

RenovoTAMP is an innovative therapy platform designed to deliver approved chemotherapeutic agents for targeted treatment of cancer tumors and is being evaluated to increase survival and improve quality of life. RenovoRx’s lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC).

About RenovoRx

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoTAMP therapy platform.

Latest News